Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation

David C. Henderson, MD

Status and phase: Terminated; Phase 4

Conditions: Schizophrenia; Schizoaffective Disorder

Treatments: Drug: Placebo; Drug: Amantadine Hydrochloride, USP

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00975611

R076477PD14002

Details and patient eligibility

About

The purpose of this study is to show that amantadine might help to reduce the side effect of the medications which are prescribed to treat schizophrenia or schizoaffective disorder. High level of hormone prolactin, or hyperprolactinemia, is one of the side effects which might be developed in patients treated with the paliperidone ER or risperidone Consta.

High level of prolactin might stimulate breast development, might decrease sexual desire (libido). The goals of this study are to demonstrate that amantadine lowers prolactin levels, decreases side effects, and improves psychiatric symptoms.

Full description

Trial Description: A double-blind, placebo-controlled, prospective, randomized trial to evaluate the effects of two doses of amantadine or placebo in the management of antipsychotic-induced hyperprolactinemia and psychiatric status in patients with schizophrenia or schizoaffective disorder who are clinically stable on paliperidone ER or risperidone Consta. Placebo or amantadine 100 mg or 200 mg BID will be administered to participants for 4 consecutive weeks as an adjunctive therapy in 72 schizophrenia subjects treated with paliperidone or risperidone Consta to examine amantadine effects on fasting AM serum prolactin levels. Participants will be followed after suspension of amantadine or placebo for an additional 4 weeks for safety purposes. The goals of this study are to prospectively demonstrate that amantadine lowers prolactin levels, and evaluate the impact of amantadine on psychiatric symptoms, and on prolactin-related side effects in patients treated with paliperidone ER or risperidone Consta.

Enrollment: 6 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female
• Age 18-65 years
• Diagnosis of schizophrenia, schizoaffective disorder, any subtype or schizophreniform disorder
• Well established compliance with out-patient medications including paliperidone ER or risperidone Consta for 3 months

Exclusion criteria

• Current substance or alcohol abuse
• Significant medical illness
• Women who are pregnant, breastfeeding, or who are unwilling or unable to use an effective form of birth control during the entire study
• Subjects treated with more than one antipsychotic drug

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

6 participants in 3 patient groups, including a placebo group

Amantadine 100mg BID

Active Comparator group

Description:

Subjects take amantadine 100mg tablets twice per day (BID)

Treatment:

Drug: Amantadine Hydrochloride, USP

Drug: Amantadine Hydrochloride, USP

Amantadine, 200mg BID

Active Comparator group

Description:

Subjects take amantadine 200mg tablets twice per day (BID)

Treatment:

Drug: Amantadine Hydrochloride, USP

Drug: Amantadine Hydrochloride, USP

Amantadine, placebo BID

Placebo Comparator group

Description:

Subjects take placebo tablets twice per day (BID)

Treatment:

Drug: Placebo